Please assess the completion status of the following clinical trial:

Trial Title: Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged between 18 years and 70 years old.~* Pathologically confirmed metastatic triple negative breast cancer (TNBC). Paraffin-embedded tissue were available from metastatic or primary sites to confirm its TNBC status or for further translational research. TNBC was defined as ER-, PR-, and HER2-.~* Metastatic TNBC should not be treated with more than 1-line for metastatic disease.~* Patients can not be treated with carboplatin in the metastatic setting.~* For patients received carboplatin treatment in the adjuvant setting, they should have at least one year disease interval between last dosage of carboplatin and trial recruiting.~* Patients had at least one measurable lesion according to RECIST criteria version 1.1.~* ECOG Performance Status (PS) of 0-1.~* Adequate liver and renal organ function.~* Dated and signed IEC/IRB-approved informed consent.~Exclusion Criteria:~* More than 1 one therapy for metastatic TNBC, Patients may receive bisphosphonates and other therapies to treat bone metastases.~* Less than four weeks since last radiotherapy.~* Pregnancy or lactation or unwillingness to use adequate method of birth control.~* Active or uncontrolled infection.~* Hypersensitivity to carboplatin or decitabine~* Male breast cancer.~* Treated with any DNA demethylating agents~* Young patients with pregnancy or lactation or unwillingness to use adequate method of birth control.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- DC (Type: EXPERIMENTAL): DNA demethylating agent decitabine plus carboplatin

Based on this trial design, predict the completion outcome and termination type (if applicable).